Mazzetti Tom, Hopman Wilma M, Couture Laura, Christilaw Erin, Munroe Jenny, Babiolakis Corinne S, Adams Michael A, Holden Rachel M
Department of Medicine, Queen's University, Kingston, ON, Canada.
Clinical Research Centre, Kingston Health Sciences Centre, Kingston General Hospital, ON, Canada.
Can J Kidney Health Dis. 2019 Jun 27;6:2054358119856891. doi: 10.1177/2054358119856891. eCollection 2019.
While dietary intake is known to influence serum markers of chronic kidney disease-mineral and bone disorder (CKD-MBD), the effects of recent food and beverage intake, particularly phosphorus consumption on these serum markers (phosphate, calcium, and parathyroid hormone [PTH]), are unknown in hemodialysis patients. An understanding of these effects could have direct and important implications on the management of CKD-MBD.
To determine whether serum phosphate, calcium, and PTH levels were higher in hemodialysis patients who had consumed dietary phosphorus within 1 hour prior to their routine dialysis-related blood work (non-phosphorus-fasted) compared with patients who did not (phosphorus-fasted).
Observational, cross-sectional study.
Kingston Health Sciences Center-Kingston General Hospital Site and its affiliated satellite hemodialysis units.
Two hundred fifty-four adult patients receiving outpatient hemodialysis treatment for end-stage kidney disease were recruited.
The main measurements for this study included an assessment of dietary phosphorus intake as well as serum phosphate, calcium, PTH, albumin, Kt/V, and urea reduction ratio.
A direct patient interview was performed to assess dietary phosphorus intake within 1 hour prior to routine dialysis-related blood work. The Canadian Nutrient File was then used to estimate dietary phosphorus based on the specific foods and beverages (including portion sizes and brands where applicable) identified in the interview. Serum measures of phosphate, PTH, calcium, albumin, and dialysis adequacy (Kt/V and urea reduction ratio) were obtained from participants' routine dialysis-related blood work.
Non-phosphorus-fasted participants had nonsignificantly higher serum PTH levels compared to phosphorus-fasted participants (61.2 ± 64.7 vs 47.9 ± 39.7, = .05). Non-phosphorus-fasted participants with PTH levels at the Kidney Disease Improving Global Outcomes (KDIGO) "target" (between 15 and 60 pmol/L) had significantly higher serum phosphate levels relative to phosphorus-fasted participants (1.6 ± 0.3 vs 1.4 ± 0.4, = .006). In non-phosphorus-fasted participants, there was a nonsignificant association between the number of items containing inorganic phosphate additives and higher levels of serum phosphate and lower levels of serum calcium.
Some limitations include the cross-sectional nature of this study, self-reporting biases and estimates (as opposed to direct measurements) related to the dietary assessment, and the use of single (and not serial) assessments of serum measures.
Dietary phosphorus intake in close proximity to blood work may contribute to subtle alterations in some key serum CKD-MBD parameters in adult outpatient hemodialysis patients but may not meaningfully alter CKD-MBD management.
虽然已知饮食摄入会影响慢性肾脏病 - 矿物质和骨代谢紊乱(CKD - MBD)的血清标志物,但近期食物和饮料摄入,特别是磷的摄入对血液透析患者这些血清标志物(磷酸盐、钙和甲状旁腺激素[PTH])的影响尚不清楚。了解这些影响可能对CKD - MBD的管理具有直接且重要的意义。
确定在进行常规透析相关血液检查前1小时内摄入膳食磷的血液透析患者(非禁食磷)与未摄入的患者(禁食磷)相比,其血清磷酸盐、钙和PTH水平是否更高。
观察性横断面研究。
金斯顿健康科学中心 - 金斯顿总医院院区及其附属卫星血液透析单位。
招募了254名接受门诊血液透析治疗的终末期肾病成年患者。
本研究的主要测量指标包括膳食磷摄入量评估以及血清磷酸盐、钙、PTH、白蛋白、Kt/V和尿素清除率。
在常规透析相关血液检查前1小时内对患者进行直接访谈,以评估膳食磷摄入量。然后根据访谈中确定的特定食物和饮料(适用时包括份量和品牌),使用加拿大营养数据库来估算膳食磷。从参与者的常规透析相关血液检查中获取磷酸盐、PTH、钙、白蛋白和透析充分性(Kt/V和尿素清除率)的血清测量值。
与禁食磷的参与者相比,非禁食磷的参与者血清PTH水平略高,但无统计学意义(61.2±64.7对47.9±39.7,P = 0.05)。甲状旁腺激素水平处于改善全球肾脏病预后组织(KDIGO)“目标”范围(15至60 pmol/L)的非禁食磷参与者,其血清磷酸盐水平相对于禁食磷的参与者显著更高(1.6±0.3对1.4±0.4,P = 0.006)。在非禁食磷的参与者中,含有无机磷酸盐添加剂的食物数量与较高的血清磷酸盐水平和较低的血清钙水平之间存在不显著的关联。
一些局限性包括本研究的横断面性质、与膳食评估相关的自我报告偏差和估计值(与直接测量相对),以及血清测量采用单次(而非连续)评估。
在血液检查前接近的时间内摄入膳食磷可能会导致成年门诊血液透析患者某些关键的CKD - MBD血清参数出现细微变化,但可能不会对CKD - MBD的管理产生有意义的改变。